Total Payments
$11,114
2024 Payments
$1,879
Companies
60
Transactions
491
Medicare Patients
907
Medicare Billing
$114,364
Payment Breakdown by Category
Food & Beverage$8,828 (79.4%)
Travel$1,182 (10.6%)
Education$605.08 (5.4%)
Other$498.50 (4.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,828 | 471 | 79.4% |
| Travel and Lodging | $1,182 | 3 | 10.6% |
| Education | $605.08 | 12 | 5.4% |
| Long term medical supply or device loan | $498.50 | 5 | 4.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca UK Limited | $1,612 | 8 | $0 (2024) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $1,269 | 64 | $0 (2023) |
| Amgen Inc. | $838.51 | 40 | $0 (2022) |
| Daiichi Sankyo Inc. | $706.65 | 44 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $502.57 | 26 | $0 (2022) |
| Janssen Biotech, Inc. | $451.00 | 24 | $0 (2024) |
| PFIZER INC. | $413.19 | 25 | $0 (2024) |
| Celgene Corporation | $381.27 | 22 | $0 (2023) |
| GENZYME CORPORATION | $360.72 | 18 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $284.99 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,879 | 12 | AstraZeneca UK Limited ($1,612) |
| 2023 | $383.62 | 5 | NOVARTIS PHARMACEUTICALS CORPORATION ($299.10) |
| 2022 | $2,907 | 161 | Novartis Pharmaceuticals Corporation ($427.97) |
| 2021 | $1,085 | 52 | Daiichi Sankyo Inc. ($291.18) |
| 2020 | $426.40 | 21 | Amgen Inc. ($125.94) |
| 2019 | $1,426 | 80 | E.R. Squibb & Sons, L.L.C. ($177.88) |
| 2018 | $2,388 | 132 | Novartis Pharmaceuticals Corporation ($269.56) |
| 2017 | $619.03 | 28 | Amgen Inc. ($231.12) |
All Payment Transactions
491 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/23/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $30.29 | General |
| Category: Oncology | ||||||
| 08/24/2024 | PFIZER INC. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Oncology | ||||||
| 06/12/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $121.33 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 03/21/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $40.07 | General |
| Category: Oncology | ||||||
| 01/30/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $584.68 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $476.83 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $120.54 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $70.00 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 06/15/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $47.70 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| 03/15/2023 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $36.82 | General |
| 02/15/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| 01/14/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| 12/15/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $28.76 | General |
| Category: Hematology | ||||||
| 12/08/2022 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: Hematology | ||||||
| 12/06/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $20.81 | General |
| Category: ONC | ||||||
| 12/05/2022 | Amgen Inc. | Kyprolis (Drug) | Food and Beverage | In-kind items and services | $16.53 | General |
| Category: Oncology | ||||||
| 12/02/2022 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $20.67 | General |
| Category: Oncology | ||||||
| 12/01/2022 | PFIZER INC. | XALKORI (Drug), INLYTA, BAVENCIO | Food and Beverage | In-kind items and services | $28.19 | General |
| Category: ONCOLOGY | ||||||
| 11/28/2022 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $2.71 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 176 | 445 | $112,806 | $27,533 |
| 2022 | 10 | 232 | 14,664 | $144,831 | $34,685 |
| 2021 | 6 | 155 | 346 | $72,912 | $17,333 |
| 2020 | 15 | 344 | 1,509 | $138,740 | $34,813 |
Total Patients
907
Total Services
16,964
Medicare Billing
$114,364
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 59 | 128 | $48,450 | $11,990 | 24.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 13 | 61 | $23,828 | $5,969 | 25.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 19 | 19 | $9,375 | $2,249 | 24.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 13 | 50 | $9,577 | $2,220 | 23.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $8,522 | $1,897 | 22.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 29 | $7,797 | $1,802 | 23.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 11 | 100 | $4,221 | $1,063 | 25.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 25 | 45 | $1,035 | $342.45 | 33.1% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2022 | 11 | 14,250 | $47,940 | $12,517 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 51 | 93 | $36,776 | $8,226 | 22.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 41 | 55 | $15,437 | $3,295 | 21.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 18 | 43 | $9,022 | $2,242 | 24.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 20 | 37 | $8,142 | $2,076 | 25.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $8,302 | $2,007 | 24.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 14 | 14 | $9,607 | $1,830 | 19.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 11 | 11 | $4,591 | $1,199 | 26.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 17 | 82 | $3,606 | $808.60 | 22.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 33 | 63 | $1,407 | $482.63 | 34.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 48 | 102 | $39,582 | $8,862 | 22.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 36 | 51 | $14,214 | $3,400 | 23.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 19 | 38 | $8,381 | $2,230 | 26.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 15 | 32 | $7,098 | $1,723 | 24.3% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 14 | 64 | $2,778 | $659.49 | 23.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 23 | 59 | $860.22 | $458.43 | 53.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 78 | 141 | $47,019 | $11,593 | 24.7% |
About Dr. Foluso Ogunleye, MD
Dr. Foluso Ogunleye, MD is a Hematology & Oncology healthcare provider based in Cerritos, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/02/2008. The National Provider Identifier (NPI) number assigned to this provider is 1972766772.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Foluso Ogunleye, MD has received a total of $11,114 in payments from pharmaceutical and medical device companies, with $1,879 received in 2024. These payments were reported across 491 transactions from 60 companies. The most common payment nature is "Food and Beverage" ($8,828).
As a Medicare-enrolled provider, Ogunleye has provided services to 907 Medicare beneficiaries, totaling 16,964 services with total Medicare billing of $114,364. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Cerritos, CA
- Active Since 07/02/2008
- Last Updated 04/15/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1972766772
Products in Payments
- KISQALI (Drug) $314.63
- JEVTANA (Drug) $305.36
- OPDIVO (Biological) $268.47
- Enhertu (Drug) $256.33
- DARZALEX (Biological) $247.55
- Cabometyx (Drug) $234.48
- ENHERTU (Drug) $222.55
- INJECTAFER (Drug) $213.24
- PROMACTA (Drug) $207.75
- LIBTAYO (Biological) $197.64
- Nplate (Biological) $194.55
- NINLARO (Drug) $189.65
- EMPLICITI (Biological) $155.15
- KEYTRUDA (Biological) $144.15
- Trodelvy (Drug) $142.44
- CYRAMZA (Drug) $138.04
- Blincyto (Biological) $134.81
- ADCETRIS (Biological) $129.04
- VYXEOS (Drug) $123.55
- Rezlidhia (Drug) $121.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Cerritos
John Khoury, Md, MD
Hematology & Oncology — Payments: $135,866
Hematology & Oncology $135,866
Farah Quyyumi, M.d, M.D
Hematology & Oncology — Payments: $10,728
Hematology & Oncology $10,728
Hiroshi Yamagata, Md, MD
Hematology & Oncology — Payments: $8,466
Hematology & Oncology $8,466
Dr. Ali Baghian, M.d, M.D
Hematology & Oncology — Payments: $8,051
Hematology & Oncology $8,051